KMTS Q1 2027 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $31 million, up 60% year-over-year and sequentially from Q4.

Gross Margin: 56.5%, an increase of over 10 points year-over-year and 175 basis points sequentially. This marks the 11th consecutive quarter of gross margin expansion.

GAAP Operating Expenses: $55.2 million, up from $37.7 million year-over-year, influenced by nonrecurring items and increased commercial expansion costs.

GAAP Net Loss: $44.1 million, compared to a loss of $25.8 million in the prior year.

Adjusted EBITDA Loss: $24 million, worsening from a loss of $19.4 million year-over-year.

Cash Position: $245 million in cash and equivalents, with total liquidity of approximately $320 million including a new $200 million term loan facility.

2Strategic Updates and Business Highlights

Market Positioning: Kestra is expanding its market share in the wearable cardioverter defibrillator (WCD) market, which is still underpenetrated; 6 out of 7 indicated patients were not protected by a WCD in 2025.

AI and Automation Initiatives: Investments in AI are aimed at improving patient support, revenue access, and sales productivity, which are expected to enhance operational efficiency and reduce costs over time.

Commercial Strategy: The company is focusing on deeper penetration in existing accounts and expanding into new territories, supported by a larger and more productive sales team.

Partnerships and Innovations: Progress with Biobeat Technologies for noninvasive blood pressure monitoring integration and ongoing R&D projects aimed at enhancing product capabilities.

3Forward Guidance and Outlook

Fiscal Year 2027 Revenue Guidance: Updated to $141 million, reflecting a 48% growth compared to FY 2026, up from a previous estimate of $137 million.

Gross Margin Target: Confidence in achieving mid-70% gross margins in the next few years, up from a prior target of 70%.

Operational Leverage: Expected improvements in operating leverage as the company scales and continues to invest in growth drivers.

4Bad News, Challenges, or Points of Concern

Net Losses: The company reported a significant net loss, which increased year-over-year, raising concerns about profitability timelines.

Cash Burn: Cash used in operations was $32.3 million, with expectations of declining burn rates throughout FY 2027, but still a notable concern.

Market Competition: Despite strong growth, the competitive landscape remains challenging, with incumbents also pushing for market share.

Operational Expenses: Higher operating expenses due to increased investments in R&D and commercial expansion may pressure profitability in the short term.

5Notable Q&A Insights

Market Expansion: Management expressed confidence in continued market growth, with a current estimate of 15% market share in the U.S. for WCDs.

Rep Productivity: New sales representatives are ramping up faster due to improved training and support, which is expected to drive higher fittings per rep in the second half of the year.

AI Impact: The company is leveraging AI to enhance sales rep productivity and improve operational efficiency, with expected benefits becoming more pronounced in FY 2028 and beyond.

Payer Coverage: A significant national payer has expanded coverage to non-ischemic patients, signaling a positive shift in payer policies influenced by clinical evidence. Overall, Kestra Medical Technologies demonstrated strong revenue growth and gross margin expansion in Q1 2027, while also outlining strategic initiatives to enhance operational efficiency and market penetration. However, ongoing net losses and cash burn present challenges that the company aims to address through improved productivity and market strategies.